Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Y C Heng

Showing results (1-10 of 214) with videos related to

Pageof 22
Sort By:
The Lancet. Oncology|June 14, 2011
Combination therapy in metastatic renal cell carcinomaDaniel Y C Heng
Journal of Oncology Practice|July 12, 2017
Renal Medullary CarcinomaDaniel Y C Heng
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 19, 2017
The next 10 years: Challenges for the future and overcoming resistance to targeted therapies for renal cell carcinomaDaniel Y C Heng
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 29, 2015
Third-line treatment in metastatic renal cell carcinoma and bone metastasesDaniel Y C Heng
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 15, 2010
SunitinibDaniel Y C Heng, Christian Kollmannsberger
BMJ Oncology|January 31, 2025
Potential of neutrophil-to-eosinophil ratio as a new prognostic tool for patients with advanced renal cell carcinoma receiving first-line immuno-oncology combinationsKosuke Takemura, Daniel Y C Heng
The Lancet. Oncology|October 16, 2023
Immunotherapy in renal cell carcinomaVishal Navani, Daniel Y C Heng
JAMA Oncology|November 18, 2021
Treatment Selection in First-line Metastatic Renal Cell Carcinoma-The Contemporary Treatment Paradigm in the Age of Combination Therapy: A ReviewVishal Navani, Daniel Y C Heng
Targeted Oncology|June 29, 2010
Prognostic and predictive biomarkers in renal cell carcinomaMichael M Vickers, Daniel Y C Heng
Nature Reviews. Nephrology|March 4, 2020
New insights into the obesity paradox in renal cell carcinomaChun Loo Gan, Daniel Y C Heng
Pageof 22

Showing results (1-10 of 214) with videos related to

Sort By:
Pageof 22
The Lancet. Oncology|June 14, 2011
Combination therapy in metastatic renal cell carcinomaDaniel Y C Heng
Journal of Oncology Practice|July 12, 2017
Renal Medullary CarcinomaDaniel Y C Heng
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 19, 2017
The next 10 years: Challenges for the future and overcoming resistance to targeted therapies for renal cell carcinomaDaniel Y C Heng
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 29, 2015
Third-line treatment in metastatic renal cell carcinoma and bone metastasesDaniel Y C Heng
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 15, 2010
SunitinibDaniel Y C Heng, Christian Kollmannsberger
BMJ Oncology|January 31, 2025
Potential of neutrophil-to-eosinophil ratio as a new prognostic tool for patients with advanced renal cell carcinoma receiving first-line immuno-oncology combinationsKosuke Takemura, Daniel Y C Heng
The Lancet. Oncology|October 16, 2023
Immunotherapy in renal cell carcinomaVishal Navani, Daniel Y C Heng
JAMA Oncology|November 18, 2021
Treatment Selection in First-line Metastatic Renal Cell Carcinoma-The Contemporary Treatment Paradigm in the Age of Combination Therapy: A ReviewVishal Navani, Daniel Y C Heng
Targeted Oncology|June 29, 2010
Prognostic and predictive biomarkers in renal cell carcinomaMichael M Vickers, Daniel Y C Heng
Nature Reviews. Nephrology|March 4, 2020
New insights into the obesity paradox in renal cell carcinomaChun Loo Gan, Daniel Y C Heng
Pageof 22